诊断和医疗保健化学品市场预测至2034年—按产品类型、应用、最终用户和地区分類的全球分析

根据 Stratistics MRC 的数据，到 2026 年，全球诊断和医疗保健化学品市场规模将达到 46 亿美元，预计在预测期内将以 7.6% 的复合年增长率增长，到 2034 年将达到 83 亿美元。

诊断和医疗保健化学原料包括用于医学检查室和医疗机构的纯化试剂、溶剂、催化剂、染色剂、缓衝液、成像化合物和检测组件。这些物质对于准确识别疾病、进行基因分析、诊断影像和监测治疗进展至关重要。它们广泛应用于体外检测、临床病理学、微生物学和药物研发，必须符合严格的纯度和监管标准。批次间生产的一致性对于确保结果的可靠性和病人安全至关重要。随着个人化医疗、照护现场诊断和生物製药的日益普及，化学研发领域的创新正在加速发展，而製造商则将配方稳定性、严格的品质保证和大规模生产的效率放在首位。

根据 Statista（医疗保健产业数据入口网站）的数据，2023 年印度诊断市场价值 130 亿美元，预计到 2028 年将翻一番，这凸显了支持这一增长所需的试剂和化学原材料的大规模消耗。

体外诊断（IVD）需求日益增长

体外诊断检测技术的日益普及显着推动了医疗保健化学原料市场的发展。慢性病和感染疾病率上升导致检查室和医院的检测频率增加。预防性医疗保健措施和大规模筛检计画也促进了试剂和检测材料的持续消耗。准确的诊断结果依赖高品质的酵素、溶剂和缓衝液，这也推动了相关采购量的成长。诊断活动的持续成长增强了生产能力，促进了供应链的优化，并支撑了医疗保健化学原料市场的长期成长。

生产成本和原料成本高

不断上涨的製造成本和波动的原材料价格是医疗化学品供应商面临的主要限制因素。生产实验室级化学品需要先进的设备、熟练的劳动力和严格的纯化程序。供应中断和对特殊原材料的依赖进一步加剧了成本的不确定性。能源消耗和合规相关支出增加了整体营运负担。医疗机构通常面临预算限制，这降低了它们应对产品价格上涨的柔软性。因此，供应商可能面临利润率下降、创新资金筹措有限以及产能扩张放缓的压力，尤其是在医疗成本受到严格控制的地区。

即时检测技术的扩展

即时诊断系统的日益普及为医疗化学品供应商带来了广阔的前景。这些部署在中心检查室之外的紧凑型检测设备，依赖可靠的预配製试剂和优化的检测组件。对快速诊断结果和在地化医疗服务日益增长的需求，正在推动产品需求的成长。在开发中国家，携带式检测平台的部署正在推进，以改善医疗服务的可近性。微流体和生物感测器整合技术的进步也增加了对高性能化学材料的需求。透过生产适用于分散式环境的耐用、易用的配方，製造商可以在这个不断发展的诊断领域开闢新的收入来源。

监理政策变化和合规不确定性

不断变化的法规结构对医疗诊断化学品供应商构成重大威胁。更新的安全指南和品质要求通常需要重新配製产品并进行额外的检验测试。政策的意外变化可能导致认证延迟，并阻碍市场准入。维持严格合规需要持续监控和大量的行政投入。国际标准的差异增加了全球业务运作的复杂性。这种不确定性会增加营运成本和法律风险，尤其对中小企业而言更是如此。随着监管压力的加剧，企业可能面临产品上市延迟、地理扩张受限以及在诊断化学品行业竞争力下降等问题。

新型冠状病毒（COVID-19）的影响：

疫情引发了全球医疗诊断化学品需求的空前激增。大规模检测计画导致分子试剂、检体运输解决方案和核酸萃取材料的使用量激增。公共和私人投资扩大了检查室容量，推动了短期市场成长。监管部门的快速核准加快了诊断试剂的上市速度。然而，运输瓶颈和供不应求暴露了全球采购网络的脆弱性。儘管做出了这些调整，但此次危机凸显了诊断化学品产业对弹性供应链、国内生产能力和持续应对能力的迫切需求。

在预测期内，试剂和试剂盒细分市场预计将占据最大的市场份额。

试剂和试剂盒领域预计将在预测期内占据最大的市场份额，因为它们在常规检查室操作中发挥至关重要的作用。这些产品广泛应用于临床检测、基因分析、疾病检测和免疫学评估。高通量检测中持续重复的使用支撑了强劲的需求。预先配置试剂盒有助于提高操作效率，确保结果的一致性，并支援现代检查室的自动化。快速诊断、专业检测和精准检测技术的进步不断拓展其应用范围，巩固了其在所有化学试剂类别中的主导地位。

预计在预测期内，生物技术诊断领域将呈现最高的复合年增长率。

在预测期内，受基因工程和分子研究进展的推动，生物技术诊断领域预计将呈现最高的成长率。随着先进生物製药和基因治疗方法的开发不断推进，对高品质试剂和特殊化学品的依赖性日益增强。定序和核酸检测的广泛应用也扩大了检查室化学品的使用量。对精准医疗和生物製药生产的大量投资进一步推动了该领域的成长。先进诊断工具和生物学研究应用的持续发展不断加速市场需求，巩固了生物技术诊断作为成长最快领域的地位。

市占率最大的地区：

在整个预测期内，北美预计将保持最大的市场份额，这得益于其先进的医疗保健基础设施以及众多领先的生物技术和製药公司。高检测频率和先进诊断技术的快速普及推动了对化学试剂的强劲需求。大量的研究经费投入和分子检测领域的创新正在促进市场扩张。完善的管理体制和优惠的报销政策确保了高品质试剂和诊断化学品的稳定供应。此外，慢性病负担的加重以及对公共卫生领域的持续投入，进一步巩固了该地区在该行业的主导地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗保健技术的加速发展和生物技术能力的不断提升。疾病负担的加重、大规模的人口基数以及诊断服务的改善，都促使检测活动日益频繁。公共和私人对製药生产和研发设施的投资，推动了化学品消费量的成长。医疗保健政策的强化和诊断基础设施的现代化，进一步提振了区域需求。此外，私人医疗网络和医疗旅游的蓬勃发展也为该地区的持续扩张提供了支持，使亚太地区成为该领域发展最快的地区。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

• 企业概况
  • 对其他市场参与者（最多 3 家公司）进行全面分析
  • 对主要企业进行SWOT分析（最多3家公司）
• 区域细分
  • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
• 竞争性标竿分析
  • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章：执行摘要

• 市场概览及主要亮点
• 驱动因素、挑战与机会
• 竞争格局概述
• 战略洞察与建议

第二章：研究框架

• 研究目标和范围
• 相关人员分析
• 研究假设和限制
• 调查方法

第三章 市场动态与趋势分析

• 市场定义与结构
• 主要市场驱动因素
• 市场限制与挑战
• 投资成长机会和重点领域
• 产业威胁与风险评估
• 技术与创新展望
• 新兴市场/高成长市场
• 监管和政策环境
• 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

• 波特五力分析
  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的竞争
• 主要企业市占率分析
• 产品基准评效和效能比较

第五章 全球诊断与医疗保健化学品市场：按产品类型划分

• 试剂和试剂盒
• 造影
• 染料和染料
• 缓衝液和溶剂
• 特种化学品

第六章 全球诊断与医疗保健化学品市场：按应用领域划分

• 临床诊断
• 出于研究目的
• 药品品管与生产
• 生物技术诊断

第七章 全球诊断与医疗保健化学品市场：按最终用户划分

• 医院和诊所
• 独立诊断检测实验室
• 学术研究机构
• 製药和生物技术公司

第八章 全球诊断与医疗保健化学品市场：按地区划分

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
  • 比利时
  • 瑞典
  • 瑞士
  • 波兰
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 印尼
  • 泰国
  • 马来西亚
  • 新加坡
  • 越南
  • 其他亚太国家
• 南美洲
  • 巴西
  • 阿根廷
  • 哥伦比亚
  • 智利
  • 秘鲁
  • 其他南美国家
• 世界其他地区（RoW）
  • 中东
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 埃及
    • 摩洛哥
    • 其他非洲国家

第九章 战略市场资讯

• 工业价值网络和供应链评估
• 空白区域和机会地图
• 产品演进与市场生命週期分析
• 通路、经销商和打入市场策略的评估

第十章：产业趋势与策略倡议

• 併购
• 伙伴关係、联盟和合资企业
• 新产品发布和认证
• 扩大生产能力和投资
• 其他策略倡议

第十一章：公司简介

• Abbott Laboratories
• Roche
• Siemens Healthineers
• Danaher
• Thermo Fisher Scientific
• bioMerieux
• Bio-Rad Laboratories
• Becton Dickinson
• Hologic
• QIAGEN
• Sysmex
• Sekisui Diagnostics
• Randox Laboratories
• Beckman Coulter
• Sigma-Aldrich
• Tulip Diagnostics
• Beijing Strong Biotechnologies
• Dojindo Laboratories

According to Stratistics MRC, the Global Diagnostics & Healthcare Chemical Inputs Market is accounted for $4.6 billion in 2026 and is expected to reach $8.3 billion by 2034 growing at a CAGR of 7.6% during the forecast period. Diagnostics and healthcare chemical inputs include refined reagents, solvents, catalysts, staining agents, buffers, imaging compounds, and assay components utilized in medical laboratories and healthcare institutions. These substances are fundamental for precise disease identification, genetic analysis, diagnostic imaging, and treatment monitoring. Widely applied in in-vitro testing, clinical pathology, microbiology, and drug development, they must meet strict purity and regulatory standards. Consistency across production batches is vital for dependable outcomes and patient protection. Rising adoption of personalized therapies, point-of-care diagnostics, and biologic medicines is accelerating innovation in chemical development, while producers emphasize formulation stability, stringent quality assurance, and large-scale manufacturing efficiency.

According to Statista (healthcare industry data portal), India's diagnostics market was valued at USD 13 billion in 2023 and is projected to double by 2028, underscoring the scale of reagent and chemical input consumption required to support this growth.

Market Dynamics:

Driver:

Rising demand for in-vitro diagnostics (IVD)

The expanding utilization of in-vitro diagnostic procedures significantly propels the healthcare chemical inputs market. Increasing cases of chronic and infectious diseases have led to higher testing frequencies across laboratories and hospitals. Preventive healthcare initiatives and mass screening programs contribute to sustained reagent and assay material consumption. Accurate diagnostic outcomes depend on premium-grade enzymes, solvents, and buffer solutions, driving procurement volumes. This continuous rise in diagnostic activity strengthens manufacturing capacity, encourages supply chain optimization, and supports long-term market growth for healthcare-focused chemical materials.

Restraint:

High production and raw material costs

Rising manufacturing expenses and unstable raw material pricing present significant limitations for healthcare chemical input providers. Producing laboratory-grade chemicals demands sophisticated facilities, skilled labor, and rigorous purification procedures. Supply disruptions and reliance on specialized source materials amplify cost uncertainty. Energy consumption and compliance-related expenditures add to overall operational burdens. Healthcare institutions often operate under budget constraints, reducing flexibility in absorbing higher product prices. As a result, suppliers may experience margin pressure, limited innovation funding, and slower capacity expansion, particularly in regions where healthcare spending remains tightly controlled.

Opportunity:

Expansion of point-of-care testing technologies

The growing adoption of point-of-care diagnostic systems creates promising prospects for healthcare chemical input suppliers. Compact testing devices deployed outside centralized laboratories depend on reliable, ready-mixed reagents and optimized assay components. Increasing preference for quick diagnostic results and community-based healthcare services strengthens product demand. Developing economies are integrating portable testing platforms to enhance medical reach. Advances in microfluidics and biosensor integration also elevate the need for high-performance chemical materials. By producing durable and easy-to-use formulations designed for decentralized environments, manufacturers can unlock new revenue streams in this expanding diagnostic segment.

Threat:

Regulatory policy changes and compliance uncertainty

Evolving regulatory frameworks represent a major threat to suppliers of healthcare diagnostic chemicals. Updated safety guidelines and quality mandates often demand product reformulation and additional validation studies. Unexpected policy shifts can postpone certifications and interrupt market access. Maintaining strict compliance requires continuous monitoring and significant administrative investment. Differences in international standards add complexity to global operations. Such unpredictability raises operational expenses and legal risks, particularly for smaller enterprises. As regulatory pressure intensifies, businesses may face delayed launches, restricted geographic expansion, and reduced competitiveness within the diagnostics chemical inputs industry.

Covid-19 Impact:

The pandemic outbreak generated an unprecedented surge in demand for healthcare diagnostic chemicals worldwide. Large-scale testing programs sharply increased usage of molecular reagents, sample transport solutions, and nucleic acid extraction materials. Public and private investments expanded laboratory capabilities, driving short-term market expansion. Rapid regulatory clearances enabled faster commercialization of diagnostic inputs. Nevertheless, transportation bottlenecks and supply shortages exposed vulnerabilities in global sourcing networks. Despite this adjustment, the crisis reinforced the need for resilient supply chains, domestic manufacturing capacity, and sustained preparedness within the diagnostics chemical inputs sector.

The reagents & kits segment is expected to be the largest during the forecast period

The reagents & kits segment is expected to account for the largest market share during the forecast period because of their critical role in everyday laboratory operations. They are widely applied in clinical testing, genetic analysis, disease detection, and immunological assessments. Ongoing and repetitive usage in large testing volumes sustains strong demand. Pre-configured kits enhance procedural efficiency, ensure consistent outcomes, and support automation in modern laboratories. Advancements in rapid diagnostics, specialized assays, and precision-based testing continue to expand their applications, reinforcing their leading position among all chemical input categories.

The biotechnology diagnostics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology diagnostics segment is predicted to witness the highest growth rate, fueled by progress in genetic engineering and molecular research. Rising development of advanced biologic drugs and gene-based therapies increases reliance on high-quality reagents and specialty chemicals. Widespread adoption of sequencing methods and nucleic acid testing expands laboratory chemical usage. Significant funding in precision healthcare and biopharmaceutical production further supports expansion. The ongoing evolution of sophisticated diagnostic tools and biologic research applications continues to accelerate demand, establishing biotechnology diagnostics as the most rapidly growing segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by its sophisticated medical infrastructure and concentration of major biotech and pharmaceutical firms. High laboratory testing frequency and rapid adoption of advanced diagnostic technologies sustain strong chemical demand. Significant research funding and innovation in molecular testing enhance market expansion. Structured regulatory systems and favorable reimbursement policies ensure steady procurement of premium reagents and laboratory chemicals. Moreover, the growing burden of chronic illnesses and ongoing public health investments further strengthen the region's leadership in this industry.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, supported by accelerating healthcare advancements and expanding biotech capabilities. Rising disease burden, large population base, and improved diagnostic accessibility contribute to increasing laboratory activity. Public and private investments in pharmaceutical manufacturing and research facilities enhance chemical consumption. Strengthening healthcare policies and modernization of diagnostic infrastructure further boost regional demand. Additionally, growth in private healthcare networks and medical tourism supports sustained expansion, making Asia-Pacific the most rapidly advancing region in this sector.

Key players in the market

Some of the key players in Diagnostics & Healthcare Chemical Inputs Market include Abbott Laboratories, Roche, Siemens Healthineers, Danaher, Thermo Fisher Scientific, bioMerieux, Bio-Rad Laboratories, Becton Dickinson, Hologic, QIAGEN, Sysmex, Sekisui Diagnostics, Randox Laboratories, Beckman Coulter, Sigma-Aldrich, Tulip Diagnostics, Beijing Strong Biotechnologies and Dojindo Laboratories.

Key Developments:

In November 2025, Siemens Healthineers and NYU Langone Health have reached a strategic agreement that will bolster the latter's imaging services throughout Manhattan, Brooklyn and Long Island. For Siemens' part of the five-year alliance between the two, they will supply NYU Langone Health with its latest gamut of advanced diagnostic imaging offerings across its network of over 300 outpatient and hospital locations.

In October 2025, Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc. from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.

In September 2025, Roche has signed a definitive merger agreement for the acquisition of clinical-stage Biopharmaceutical Company 89bio, for a total equity value of around $2.4bn. Under the deal, Roche will initiate a tender offer to purchase all outstanding shares of 89bio common stock at $14.50 per share in cash.

Product Types Covered:

• Reagents & Kits
• Contrast Agents
• Stains & Dyes
• Buffers & Solvents
• Specialty Chemicals

Applications Covered:

• Clinical Diagnostics
• Research Applications
• Pharmaceutical Quality & Manufacturing
• Biotechnology Diagnostics

End Users Covered:

• Hospitals & Clinics
• Independent Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Diagnostics & Healthcare Chemical Inputs Market, By Product Type

• 5.1 Reagents & Kits
• 5.2 Contrast Agents
• 5.3 Stains & Dyes
• 5.4 Buffers & Solvents
• 5.5 Specialty Chemicals

6 Global Diagnostics & Healthcare Chemical Inputs Market, By Application

• 6.1 Clinical Diagnostics
• 6.2 Research Applications
• 6.3 Pharmaceutical Quality & Manufacturing
• 6.4 Biotechnology Diagnostics

7 Global Diagnostics & Healthcare Chemical Inputs Market, By End User

• 7.1 Hospitals & Clinics
• 7.2 Independent Diagnostic Laboratories
• 7.3 Academic & Research Institutes
• 7.4 Pharmaceutical & Biotechnology Companies

8 Global Diagnostics & Healthcare Chemical Inputs Market, By Geography

• 8.1 North America
  • 8.1.1 United States
  • 8.1.2 Canada
  • 8.1.3 Mexico
• 8.2 Europe
  • 8.2.1 United Kingdom
  • 8.2.2 Germany
  • 8.2.3 France
  • 8.2.4 Italy
  • 8.2.5 Spain
  • 8.2.6 Netherlands
  • 8.2.7 Belgium
  • 8.2.8 Sweden
  • 8.2.9 Switzerland
  • 8.2.10 Poland
  • 8.2.11 Rest of Europe
• 8.3 Asia Pacific
  • 8.3.1 China
  • 8.3.2 Japan
  • 8.3.3 India
  • 8.3.4 South Korea
  • 8.3.5 Australia
  • 8.3.6 Indonesia
  • 8.3.7 Thailand
  • 8.3.8 Malaysia
  • 8.3.9 Singapore
  • 8.3.10 Vietnam
  • 8.3.11 Rest of Asia Pacific
• 8.4 South America
  • 8.4.1 Brazil
  • 8.4.2 Argentina
  • 8.4.3 Colombia
  • 8.4.4 Chile
  • 8.4.5 Peru
  • 8.4.6 Rest of South America
• 8.5 Rest of the World (RoW)
  • 8.5.1 Middle East
    • 8.5.1.1 Saudi Arabia
    • 8.5.1.2 United Arab Emirates
    • 8.5.1.3 Qatar
    • 8.5.1.4 Israel
    • 8.5.1.5 Rest of Middle East
  • 8.5.2 Africa
    • 8.5.2.1 South Africa
    • 8.5.2.2 Egypt
    • 8.5.2.3 Morocco
    • 8.5.2.4 Rest of Africa

9 Strategic Market Intelligence

• 9.1 Industry Value Network and Supply Chain Assessment
• 9.2 White-Space and Opportunity Mapping
• 9.3 Product Evolution and Market Life Cycle Analysis
• 9.4 Channel, Distributor, and Go-to-Market Assessment

10 Industry Developments and Strategic Initiatives

• 10.1 Mergers and Acquisitions
• 10.2 Partnerships, Alliances, and Joint Ventures
• 10.3 New Product Launches and Certifications
• 10.4 Capacity Expansion and Investments
• 10.5 Other Strategic Initiatives

11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Roche
• 11.3 Siemens Healthineers
• 11.4 Danaher
• 11.5 Thermo Fisher Scientific
• 11.6 bioMerieux
• 11.7 Bio-Rad Laboratories
• 11.8 Becton Dickinson
• 11.9 Hologic
• 11.10 QIAGEN
• 11.11 Sysmex
• 11.12 Sekisui Diagnostics
• 11.13 Randox Laboratories
• 11.14 Beckman Coulter
• 11.15 Sigma-Aldrich
• 11.16 Tulip Diagnostics
• 11.17 Beijing Strong Biotechnologies
• 11.18 Dojindo Laboratories

List of Tables

• Table 1 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Region (2023-2034) ($MN)
• Table 2 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Product Type (2023-2034) ($MN)
• Table 3 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Reagents & Kits (2023-2034) ($MN)
• Table 4 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Contrast Agents (2023-2034) ($MN)
• Table 5 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Stains & Dyes (2023-2034) ($MN)
• Table 6 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Buffers & Solvents (2023-2034) ($MN)
• Table 7 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Specialty Chemicals (2023-2034) ($MN)
• Table 8 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Application (2023-2034) ($MN)
• Table 9 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Clinical Diagnostics (2023-2034) ($MN)
• Table 10 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Research Applications (2023-2034) ($MN)
• Table 11 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Pharmaceutical Quality & Manufacturing (2023-2034) ($MN)
• Table 12 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Biotechnology Diagnostics (2023-2034) ($MN)
• Table 13 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By End User (2023-2034) ($MN)
• Table 14 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
• Table 15 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Independent Diagnostic Laboratories (2023-2034) ($MN)
• Table 16 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
• Table 17 Global Diagnostics & Healthcare Chemical Inputs Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.